Afssaps suspend the authorization of placing on the market buflomedil, six weeks after the request for its withdrawal by the Independent Prescribing which, on January 4 last, had found the product likely to cause "adverse neurological and heart, sometimes fatal. "
Pending reform of pharmacovigilance announced by Health Minister Xavier Bertrand, the controversy surrounding the drug after another. Into the trap of scandal Picks and publishing a list of 77 potentially dangerous drugs, that the French Agency for Sanitary Safety of Health Products (AFSSAPS) is very interested in Buflomedil. Constable believes that the drug product for therapeutic effects presents real dangers to health, and more specifically " risk of serious side effects neurological and cardiac . A suspension of the authorization of placing on the market has therefore been decided for 17 drugs containing buflomedil, the vasodilator and Fonzylane. According
Afssaps buflomedil, which was marketed in France since 1974, was responsible for seizures, hypotension, seizures and problems (or even stops) heart. Lots of buflomedil on the market were recalled, and the agency has asked doctors not to prescribe the drugs concerned. Pharmacists are encouraged to do more and deliver, and patients are encouraged to turn to alternative care therapies.
0 comments:
Post a Comment